Spectrum Pharmaceuticals and Allergan announced that the FDA has granted fast track designation to EOquin (apaziquone) for the treatment of non-muscle invasive bladder cancer, a form of bladder cancer localized in the surface layers of the bladder that has not spread to the deeper muscle layer. In a marker lesion study, where patients had previously failed multiple therapies, apaziquone produced a 67% complete response and was well-tolerated. Spectrum is continuing to investigate the efficacy and safety of EOquin in Phase 3 studies.
EOquin is a quinone based bioreductive prodrug activated by reductive enzymes produced by bladder tumor cells, to form a cytotoxic alkylating agent.
For more information call (877) 387-4538 or visit www.spectrumpharm.com.